DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Banzel (Rufinamide) - Summary



BANZEL™ (rufinamide) Tablets

BANZEL (rufinamide) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs).

BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.

See all Banzel indications & dosage >>


Media Articles Related to Banzel (Rufinamide)

Fycompa (perampanel) receives European MA for PGTC seizures in patients with idiopathic generalised epilepsy
Source: Epilepsy News From Medical News Today [2015.06.26]
The European Commission (EC) has today granted marketing authorisation approval for Fycompa® (perampanel), for use as a once-daily, adjunctive therapy for primary generalised tonic-clonic...

Scientists identify amino acid that stops seizures in mice
Source: Epilepsy News From Medical News Today [2015.06.22]
Finding suggests novel mechanism for treating epilepsyAn amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by...

Febrile Seizures
Source: MedicineNet Cerebral Palsy Specialty [2015.06.08]
Title: Febrile Seizures
Category: Diseases and Conditions
Created: 5/9/2008 12:00:00 AM
Last Editorial Review: 6/8/2015 12:00:00 AM

Recommendations address how to manage seizures in infants
Source: Epilepsy News From Medical News Today [2015.06.03]
New recommendations offer insights on strategies for treating infants with seizures.

Antidepressants Linked to First-Time Seizures
Source: MedicineNet bupropion Specialty [2015.04.09]
Title: Antidepressants Linked to First-Time Seizures
Category: Health News
Created: 4/9/2015 12:00:00 AM
Last Editorial Review: 4/9/2015 12:00:00 AM

more news >>

Published Studies Related to Banzel (Rufinamide)

Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. [2011.05]
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic drug from all double-blind, add-on, randomized, placebo-controlled clinical trials published to date.

Rufinamide for the treatment of Lennox-Gastaut syndrome. [2011.04]
INTRODUCTION: Lennox-Gastaut syndrome (LGS) is a severe treatment-resistant childhood-onset epilepsy. This review examines the role of the new drug rufinamide for the treatment of LGS...

A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. [2011.02]
PURPOSE: Efficacy and safety of adjunctive rufinamide (3,200 mg/day) was assessed in adolescents and adults with inadequately controlled partial-onset seizures receiving maintenance therapy with up to three antiepileptic drugs (AEDs)... CONCLUSIONS: Adjunctive treatment with rufinamide reduced total partial seizures in refractory patients. AEs reported were consistent with the known tolerability profile of rufinamide. Wiley Periodicals, Inc. (c) 2010 International League Against Epilepsy.

Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects. [2011.01]
BACKGROUND: Rufinamide is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged >/=4 years. OBJECTIVES: The primary purpose of this study was to compare the relative bioavailability and other pharmacokinetics of rufinamide administered as a 400-mg tablet formulation (reference) with 10 mL of a newly developed 40-mg/mL suspension (test) manufactured using 3 different homogenization speeds in healthy subjects under fed conditions. The study also explored whether homogenization speed had any effect on rufinamide pharmacokinetics when administered as a suspension formulation... CONCLUSION: This single-dose study in a small population of fed, healthy subjects found no statistically significant differences in relative bioavailability among each of the 3 test suspensions and the currently marketed 400-mg tablet formulation of rufinamide, meeting FDA and EMA regulatory requirements for assuming bioequivalence. Copyright (c) 2011 Elsevier HS Journals, Inc. All rights reserved.

Update on rufinamide in childhood epilepsy. [2011]
Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1) methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticonvulsant drugs. It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in the United States in 2004, and released for use in Europe in 2007.

more studies >>

Clinical Trials Related to Banzel (Rufinamide)

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs [Recruiting]

Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome [Recruiting]
The purpose of this study is to test if rufinamide has an effect on chronic neuropathic pain in patients with a post thoracotomy pain syndrome.

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients [Recruiting]
To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.

Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome [Recruiting]
This surveillance's objectives are 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Efficacy during long-term administration 4. Factors considered to have effect to safety and effectiveness 5. Incidences of status epileptics, skin disorders and hyper sensitivity reaction, and central nervous system-related adverse events(ataxia , somnolence and/or dizzy, etc.)

Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study [Recruiting]
Untersuchungen über die Wirkmechanismen von Antiepileptika haben gezeigt, dass durch eine Blockierung von spannungsabhängigen Natrium-Kanälen im Nervensystem die Schmerzübertragung moduliert werden kann. Verschiedene Antiepileptika werden in der chronischen Schmerztherapie schon lange angewendet (z. B. Oxcarbazepinum, Trileptal ® bei Trigeminusneuralgie oder diabetischer Polyneuropathie).

In unserer Untersuchung wollen wir zwei in der Schweiz zugelassene Antiepileptika bezüglich ihrer Wirkung auf das Schmerzempfinden untersuchen. Eines dieser Medikamente, Trileptal® (Wirkstoff: Oxcarbazepinum), wird schon häufig bei chronischen Schmerzzuständen eingesetzt. Das zweite Medikament, Inovelon® (Wirkstoff: Rufinamid) ist seit mehr als einem Jahr in der Schweiz zugelassen und wird klinisch vor allem in der Behandlung von besonderen Epilepsieformen im Kindesalter eingesetzt. Wir erwarten, dass auch nach Gabe von Inovelon® die Schmerzleitung in den Nervenzellen verändert und die lokalen Schmerzreaktionen in der Haut vermindert werden.

- Trial with medicinal product

more trials >>

Reports of Suspected Banzel (Rufinamide) Side Effects

Vomiting (4)Pneumonia Aspiration (3)Dehydration (3)Aphasia (2)Sudden Unexplained Death in Epilepsy (2)Emotional Disorder (2)Crying (2)Blood Potassium Decreased (2)Confusional State (1)Excessive Eye Blinking (1)more >>

Page last updated: 2015-06-26

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015